New insights in management and prognosis in acute myocardial infarction
Kampinga, Marthe Anna

Important Note: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2015

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 08-12-2023
Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: The Comparison of IntraCoronary versus intravenous abciximab administration during Emergency Reperfusion Of ST-segment elevation myocardial infarction (CICERO) trial
Abstract

Background
Administration of the glycoprotein IIb/IIIa inhibitor abciximab is an effective adjunctive treatment strategy during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Although small-scale studies have suggested beneficial effects of intracoronary over intravenous administration of abciximab, this has not been investigated in a medium-scale randomized clinical trial.

Methods and Results
A total of 534 ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with thrombus aspiration within 12 hours of symptom onset were randomized to either an intracoronary or an intravenous bolus of abciximab (0.25 mg/kg). Patients were pretreated with aspirin, heparin, and clopidogrel. The primary end point was the incidence of restored myocardial reperfusion, defined as complete ST-segment resolution. Secondary end points included myocardial reperfusion as assessed by myocardial blush grade, enzymatic infarct size, and major adverse cardiac events at 30 days. The incidence of complete ST-segment resolution was similar in the intracoronary and intravenous groups (64% versus 62%; p=0.562). However, the incidence of myocardial blush grade 2/3 was higher in the intracoronary group than in the intravenous group (76% versus 67%; p=0.022). Furthermore, enzymatic infarct size was smaller in the intracoronary than in the intravenous group (p=0.008). The incidence of major adverse cardiac events was similar in both groups (5.5% versus 6.1%; p=0.786).

Conclusions
In ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with thrombus aspiration, intracoronary administration of abciximab compared with intravenous administration does not improve myocardial reperfusion as assessed by ST-segment resolution. However, intracoronary administration is associated with improved myocardial reperfusion as assessed by myocardial blush grade and a smaller enzymatic infarct size.

Clinical Trial Registration ClinicalTrials.gov NCT00927615
Introduction

ST-segment elevation myocardial infarction (STEMI) is a clinical condition caused by rupture or erosion of an atherosclerotic plaque and subsequent platelet aggregation and thrombosis, resulting in acute occlusion of a coronary artery. Prompt reperfusion therapy with primary percutaneous coronary intervention (PCI) has become the treatment strategy of choice. Recently, the implementation of adjunctive mechanical and pharmacological therapies during primary PCI, including manual thrombus aspiration and glycoprotein (GP) IIb/IIIa inhibitors, has improved myocardial reperfusion and clinical outcome in STEMI patients. In large randomized trials, intravenous administration of the GP IIb/IIIa inhibitor abciximab during primary PCI reduced short- and long-term mortality and reinfarction rates in patients with STEMI. Recently, experimental studies have suggested that abciximab exerts additional antiplatelet, antithrombotic, and antiinflammatory effects when local drug concentrations are higher. A recent study has reported that local GP IIb/IIIa receptor inhibition is higher with intracoronary administration of the GP IIb/IIIa inhibitor eptifibatide. Therefore, a higher local drug concentration by intracoronary administration of abciximab is expected to further improve clinical outcome. Although small- to medium-scale registries and randomized clinical trials have suggested beneficial clinical effects of intracoronary administration, this has not been investigated in a medium-scale randomized clinical trial with an adequate number of patients to assess myocardial reperfusion. Furthermore, there is no information at present with regard to the combined strategy of thrombus aspiration and intracoronary abciximab administration. Therefore, we investigated whether intracoronary administration of abciximab is superior to intravenous administration in improving myocardial reperfusion in STEMI patients undergoing primary PCI with thrombus aspiration.

Methods

Study design and population
The Comparison of IntraCoronary versus intravenous abciximab administration during Emergency Reperfusion Of ST-segment elevation myocardial infarction (CICERO) trial was a single-center, prospective, randomized, open-label trial with blinded evaluation of end points. The detailed study design has been published previously. Between September 2008 and April 2010, consecutive STEMI patients undergoing primary PCI were randomly assigned to either an intracoronary or an intravenous bolus of abciximab (0.25 mg/kg body weight; ReoPro 2 mg/mL; Centocor BV, Leiden, the Netherlands). This study was performed at a high-volume university medical center providing 24-hour emergency cardiac care with 7 referral hospitals in a region of 750,000 inhabitants. The study was approved by the Medical
Ethics Review Committee of the University Medical Center of Groningen. All patients gave informed consent.

All STEMI patients who were candidates for primary PCI were considered eligible for participation. STEMI was defined as chest pain suggestive of myocardial ischemia for at least 30 minutes before hospital admission, time from symptom onset of <12 hours, and an ECG with new ST-segment elevation in 2 or more contiguous leads of ≥0.2 mV in leads V2 to V3 and/or ≥0.1 mV in other leads or a new-onset left bundle-branch block. Exclusion criteria were rescue PCI after thrombolytic therapy, need for emergency coronary artery bypass grafting, presence of cardiogenic shock, a life expectancy of <6 months, inability to provide informed consent, age <18 years, and contraindications for the use of abciximab, including active internal bleeding, history of stroke within 2 years, recent major surgery or trauma, intracranial neoplasm, arteriovenous malformation or aneurysm, bleeding diathesis, severe uncontrolled hypertension, thrombocytopenia, vasculitis, hypertensive or diabetic retinopathy, severe liver or kidney failure, and hypersensitivity to murine proteins.

Treatment
Patients were pretreated with aspirin (500 mg), heparin (5000 IU), and high-dose clopidogrel (600 mg), usually in the ambulance. When prasugrel became available in certain ambulances in 2010, use of prasugrel (60 mg) instead of clopidogrel was allowed. After diagnostic coronary angiography was performed, patients who met the eligibility criteria were randomized by means of sealed envelopes. After randomization, a bolus of abciximab was administered through the guiding catheter proximal to the lesion in the infarct-related artery over a period of 1 minute in patients assigned to intracoronary administration directly after first restoration of antegrade flow. The preferred initial treatment step to restore antegrade flow consisted of manual thrombus aspiration (Export Aspiration Catheter; Medtronic Inc, Santa Rosa, Calif) under continuous suction. In patients assigned to intravenous administration, abciximab was administered during PCI, but the exact timing of administration was not specified by protocol. Additional predilatation or postdilatation with a balloon and stent implantation were at the discretion of the operator. Intracoronary administration of nitroglycerine (400 μg) was administered periprocedurally at the operator’s discretion. During PCI, additional low-dose weight-adjusted heparin was administered as guided by the activated clotting time (target, 200 to 250 seconds). No 12-hour infusion was initiated after PCI. Standard therapy after PCI included aspirin, clopidogrel, β-blockers, lipid-lowering agents, and angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, according to current international guidelines.¹⁴

End points
The primary end point was the incidence of restored myocardial reperfusion, defined as
complete ST-segment resolution (STR). Secondary end points of myocardial reperfusion included myocardial blush grade (MBG) and residual ST-segment deviation. Other secondary end points included incidence of Q waves, postprocedural Thrombolysis in Myocardial Infarction (TIMI) flow and angiographically visible distal embolization, enzymatic infarct size, all-cause mortality, and major adverse cardiac events (a combined end point of cardiac mortality, reinfarction, and target vessel revascularization) at 30 days. A safety end point consisted of in-hospital bleeding, defined according to the TIMI bleeding classification.15

**ECG analysis**
For evaluation of the ECG end points, a 12-lead ECG was acquired at the time of presentation and at 30 to 60 minutes after primary PCI. The magnitude of ST-segment deviation was measured 60 minutes from the J point. STR was assessed by comparing the ST-segment deviation in the infarct-related area on the ECG after PCI with the ECG at presentation and was categorized as complete (>70%), partial (30% to 70%), or absent (<30%), as previously described.16 On the ECG after PCI, residual ST-segment deviation was categorized as <2, 2 to 5, 5 to 10, or >10 mm by summing the residual ST-segment deviation as previously described.17 New-onset Q waves on the ECG after PCI were defined as an initial negative deflection of the QRS complex of >0.1 mV and >40 ms in an ECG lead related to the myocardial area of infarction together with all pathological Q waves.18 All ECG recordings were analyzed by a physician blinded to treatment allocation and clinical data. When in doubt, the recordings were reviewed by 2 additional physicians until consensus was reached.

**Angiographic analysis**
MBG was categorized as follows:0=no myocardial blush, or contrast density; 1=minimal myocardial blush; 2=moderate myocardial blush but less than that obtained during angiography of a contralateral or ipsilateral non–infarct-related coronary artery; and 3=normal myocardial blush comparable to that obtained during angiography of a contralateral or ipsilateral non–infarct-related coronary artery. In addition, MBG was measured with the quantitative blush evaluator, which provides a computer-assisted and continuous score.20 TIMI flow was defined as previously described.21 Distal embolization after PCI was defined as a new circumscribed filling defect and/or abrupt cutoff of the vessel distal to the target lesion.22 Thrombus was assessed according to the criteria of the TIMI group.23 Coronary angiograms were analyzed by 2 physicians blinded to treatment allocation and clinical data until consensus was reached.

**Infarct size**
Infarct size was estimated by serial measurements of cardiac markers, including creatine kinase, creatine kinase-MB, and cardiac troponin T. Blood was sampled at baseline and at 3,
6, 9, 12, 18, 24, and 48 hours after PCI in patients who were hospitalized in this center after PCI. Peak release, time to peak release, and area under the curve over the first 48 hours were determined. If patients were observed for shorter periods, the area under the curve was estimated by multiplying the time-averaged mean level by 48 hours (adjusted values).

Clinical follow-up
Clinical follow-up was obtained from the central personal records database, hospital records, and interviews with the patients and/or their general practitioners. Mortality was considered cardiac unless an unequivocal noncardiac cause of death was established. Reinfarction was defined as recurrent symptoms suggestive of ischemia with new ST-segment elevation and/or elevation of the levels of cardiac markers. Target vessel revascularization was defined as ischemia-driven revascularization of the infarct-related artery with PCI or coronary artery bypass grafting. Clinical events were adjudicated by a committee consisting of 3 physicians blinded to treatment allocation.

Sample size and statistical analysis
In previously published data, complete STR was achieved in 56.6% of STEMI patients treated with thrombus aspiration. To detect a 25% increase in the incidence of this primary end point in patients randomized to the intracoronary group, a total of 530 patients were required to achieve 90% power at a 5% significance level (2 sided), allowing 10% of ECGs to be not assessable for the primary end point. Statistical analyses were performed by intention to treat. Statistical significance was considered at a 2-tailed value of p<0.05. Differences between group means were assessed with the 2-tailed Student t test or Mann-Whitney U test if samples were not normally distributed. The χ2 or Fisher exact test was used to test differences between proportions. Statistical analyses were performed with the Statistical Package for the Social Sciences version 16.0.2 (SPSS Inc, Chicago, Ill). Investigators had full access to all primary data.

Results
A total of 534 STEMI patients were randomly assigned to either intracoronary (n=271) or intravenous (n=263) abciximab administration (Figure 1). A total of 80 patients were excluded because of a contraindication for the use of abciximab (n=38), an inability to provide informed consent (n=2), cardiogenic shock (n=38), and need for emergency coronary artery bypass grafting (n=2). Baseline characteristics did not differ significantly between patients randomized to intracoronary or intravenous administration (Table 1). Clopidogrel was administered routinely before PCI in the prehospital setting either in
the ambulance or at the referral hospital. In patients admitted through the emergency department (9%), clopidogrel was administered before transportation for PCI. In 3%, clopidogrel was administered after PCI. Prasugrel was administered instead of clopidogrel in 2 patients randomized to intracoronary administration and 4 randomized to intravenous administration. Abciximab was administered after a median time of 3 minutes (interquartile range [IQR], 2 to 5 minutes) in the intracoronary group and 1 minute (IQR, 0–3 minutes) in

**Figure 1 | Flowchart of patient enrollment**

- 614 patients with STEMI undergoing primary PCI assessed
  - 80 patients did not meet eligibility criteria
  - 534 patients randomized between September 2008 and April 2010
    - 271 assigned to IC bolus of abciximab (0.25 mg/kg) - 3 cross-over to IV bolus
    - 263 assigned to IV bolus of abciximab (0.25 mg/kg) - no cross-over to IC bolus
    - 266 thrombus aspiration
      - Electrocardiographic endpoints including primary endpoint available in 251 patients
        - Angiographic endpoints available in 266 patients
          - Enzymatic infarct size available in 126 patients
            - Clinical outcome at 30 days available in 271 patients
        - Electrocardiographic endpoints including primary endpoint available in 237 patients
          - Angiographic endpoints available in 260 patients
            - Enzymatic infarct size available in 122 patients
              - Clinical outcome at 30 days available in 263 patients

the intravenous group from first intracoronary intervention \((p<0.001)\). Crossovers occurred nonintentionally in 3 patients randomized to intracoronary administration.

**ECG end points**
The primary end point of complete STR was achieved in 64% of the intracoronary group and 62% of the intravenous group \((p=0.562)\). STR could not be assessed in 20 of 271 patients (7.4%) in the intracoronary group and 26 of 263 patients (9.9%) of the intravenous group \((p=0.302)\) because no pre-PCI ECG was available \((n=11)\), no post-PCI ECG was available \((n=24)\), or conduction abnormalities or arrhythmias were seen on the ECG \((n=11)\). Patients without primary end-point analysis were slightly older, had a longer ischemic time, and more often had hypercholesterolemia, multivessel disease, and the left main, graft, or right coronary artery as the infarct-related artery. Concordantly, there were no differences in the distributions of residual ST-segment deviation between the intracoronary and intravenous groups \((p=0.662; \text{Figure 2})\). The incidence and number of Q waves on the postprocedural ECG were similar in both groups \((77\% \text{ versus } 82\%; \text{p}=0.143; \text{median, 2 [IQR, 1 to 3] versus 2 [IQR, 1 to 4]; p=0.114})\). The median time from abciximab administration to the ECG after PCI was 4 minutes shorter for the intracoronary than for the intravenous group \((38 \text{ minutes [IQR, 31 to 49 minutes] versus 42 minutes [IQR, 33 to 74 minutes]; p<0.001})\).

**Angiographic end points**
Coronary angiograms were assessable in 526 of 534 patients \((99\%)\). In contrast to the distribution of ECG end points, the distribution of MBG was borderline significant in favor of patients randomized to intracoronary administration \((p=0.052; \text{Figure 2})\). Moreover, the incidence of MBG 2/3 was significantly higher in the intracoronary than in the intravenous group \((76\% \text{ versus } 67\%; \text{p=0.022})\). When measured quantitatively with the quantitative blush evaluator \((available \text{ in 75\% of patients})\), myocardial reperfusion was slightly better in the intracoronary group than in the intravenous group, but this was not statistically significant \((10.1\pm3.5 \text{ versus } 9.7\pm3.6; \text{p=0.269})\). After thrombus aspiration, assessable in 90\% of patients, flow was restored \((\text{TIMI grade 2/3})\) in 211 of 235 patients \((90\%)\) in the intracoronary group and 201 of 232 patients \((87\%)\) in the intravenous group \((p=0.291)\). Postprocedural TIMI grade 3 flow was achieved in 89\% and 86\% of the intracoronary and intravenous groups, respectively \((p=0.261)\). Postprocedural distal embolization occurred at similar frequencies between both groups \((12\% \text{ and } 13\%, \text{respectively}; \text{p=0.635})\). The median time from abciximab administration to the angiographic run containing the blush sequence was 1 minute shorter for the intracoronary than for the intravenous group \((8 \text{ minutes [IQR, 5 to 12 minutes] versus 9 minutes [IQR, 6 to 15 minutes]; p=0.006})\).
Table 1 | Baseline characteristics of the 534 patients randomized to intracoronary or intravenous administration of abciximab

<table>
<thead>
<tr>
<th>Clinical</th>
<th>Intracoronary (n=271)</th>
<th>Intravenous (n=263)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>64±13</td>
<td>64±13</td>
<td>0.940</td>
</tr>
<tr>
<td>Male sex</td>
<td>208/271 (77)</td>
<td>187/263 (71)</td>
<td>0.137</td>
</tr>
<tr>
<td>Hypertension</td>
<td>119/270 (44)</td>
<td>129/263 (49)</td>
<td>0.250</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>80/268 (30)</td>
<td>74/261 (28)</td>
<td>0.705</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>36/271 (13)</td>
<td>29/263 (11)</td>
<td>0.425</td>
</tr>
<tr>
<td>Family history</td>
<td>125/267 (47)</td>
<td>124/262 (47)</td>
<td>0.906</td>
</tr>
<tr>
<td>Current smoking</td>
<td>116/270 (43)</td>
<td>127/263 (48)</td>
<td>0.217</td>
</tr>
<tr>
<td>Previous MI</td>
<td>32/271 (12)</td>
<td>23/262 (9)</td>
<td>0.250</td>
</tr>
<tr>
<td>Previous PCI</td>
<td>25/271 (9)</td>
<td>21/262 (8)</td>
<td>0.619</td>
</tr>
<tr>
<td>Previous CABG</td>
<td>6/271 (2)</td>
<td>5/263 (2)</td>
<td>0.799</td>
</tr>
<tr>
<td>Preinfarction angina</td>
<td>73/270 (27)</td>
<td>76/263 (29)</td>
<td>0.632</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>27±4</td>
<td>27±5</td>
<td>0.929</td>
</tr>
<tr>
<td>Systolic blood pressure, mmHg</td>
<td>131±27</td>
<td>129±25</td>
<td>0.319</td>
</tr>
<tr>
<td>Diastolic blood pressure, mmHg</td>
<td>76±15</td>
<td>74±13</td>
<td>0.231</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>78±18</td>
<td>78±18</td>
<td>0.196</td>
</tr>
<tr>
<td>Ischemic time, min</td>
<td>180 (120–275)</td>
<td>179 (128–275)</td>
<td>0.567</td>
</tr>
<tr>
<td>No. of diseased vessels</td>
<td>123/271 (45)</td>
<td>101/261 (39)</td>
<td>0.295</td>
</tr>
<tr>
<td>1</td>
<td>78/271 (29)</td>
<td>84/261 (32)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>70/271 (26)</td>
<td>76/261 (29)</td>
<td></td>
</tr>
<tr>
<td>Infarct-related artery</td>
<td>121/271 (45)</td>
<td>124/263 (47)</td>
<td>0.844</td>
</tr>
<tr>
<td>LAD</td>
<td>33/271 (12)</td>
<td>34/263 (13)</td>
<td></td>
</tr>
<tr>
<td>Cx</td>
<td>112/271 (41)</td>
<td>99/263 (38)</td>
<td></td>
</tr>
<tr>
<td>RCA</td>
<td>5/271 (2)</td>
<td>6/263 (2)</td>
<td></td>
</tr>
<tr>
<td>TIMI flow grade</td>
<td>0.050</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>125/271 (46)</td>
<td>145/263 (55)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>25/271 (9)</td>
<td>31/263 (12)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>64/271 (24)</td>
<td>49/263 (19)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>57/271 (21)</td>
<td>38/263 (14)</td>
<td></td>
</tr>
<tr>
<td>Thrombus present</td>
<td>236/270 (87)</td>
<td>242/263 (92)</td>
<td>0.080</td>
</tr>
<tr>
<td>Collaterals present</td>
<td>52/266 (20)</td>
<td>48/256 (19)</td>
<td>0.817</td>
</tr>
<tr>
<td>Thrombosis aspiration</td>
<td>266/271 (98)</td>
<td>255/263 (97)</td>
<td>0.370</td>
</tr>
<tr>
<td>Balloon predilatation</td>
<td>119/271 (44)</td>
<td>126/263 (48)</td>
<td>0.354</td>
</tr>
<tr>
<td>Stent implantation</td>
<td>256/271 (95)</td>
<td>251/263 (95)</td>
<td>0.608</td>
</tr>
</tbody>
</table>
| Thrombolysis In Myocardial Infarction, IABP: intra-aortie balloon pumping.

Data are presented as mean±SD, median (IQR) or as number/total number (%).
Infarct size
Data on enzymatic infarct size could be assessed in 248 of 534 patients (46%). Infarct size was ≈30% smaller in the intracoronary group than in the intravenous group (1214 U/L [IQR, 488 to 2184 U/L] versus 1746 U/L [IQR, 733 to 3383 U/L] for creatine kinase, p=0.008; 154 U/L [IQR, 62 to 262 U/L] versus 232 U/L [IQR, 90 to 400 U/L] for creatinine kinase-MB, p=0.003; and 3.03 μg/L [IQR, 0.95 to 5.81 μg/L] versus 4.36 μg/L [IQR, 1.43 to 8.56 μg/L] for cardiac troponin T, p=0.008; Table 2).

Figure 2 | Distribution of myocardial reperfusion as assessed by (A) ST-segment resolution (STR), (B) residual ST-segment deviation, and (C) myocardial blush grade (MBG) in patients randomized to intracoronary or intravenous administration of abciximab.

Although the distribution of STR and residual ST-segment deviation was not different for both groups (p=0.844 and p=0.662, respectively), the distribution of MBG was borderline significant in favor of patients randomized to intracoronary administration (p=0.052).
Clinical follow-up
In total, 12 patients (2.2%) died within 30 days. All-cause mortality was 1.8% and 2.7% in the intracoronary and intravenous groups, respectively (p=0.524; Table 3). The incidence of major adverse cardiac events was low and not significantly different between the 2 groups (5.5% in the intracoronary group versus 6.1% in the intravenous group; p=0.786).

Safety
There were no adverse procedural events related to intracoronary abciximab administration. The incidence of in-hospital major and minor bleeding was low and similar between the intracoronary and intravenous groups (for major bleeding, 3.7% versus 3.4%, p=0.867; for minor bleeding, 7.7% versus 6.8%, p=0.688). In-hospital thrombocytopenia <150×10^9/L developed in patients randomized to intracoronary and intravenous administration at similar frequencies (12% versus 13%; p=0.794).

Table 2 | Enzymatic infarct size in patients with complete in-hospital follow-up

<table>
<thead>
<tr>
<th></th>
<th>Intracoronary (n=126)</th>
<th>Intravenous (n=122)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peak CK, U/L</td>
<td>1214 (488–2184)</td>
<td>1746 (733–3383)</td>
<td>0.008</td>
</tr>
<tr>
<td>Peak CK-MB, U/L</td>
<td>154 (62–262)</td>
<td>232 (90–400)</td>
<td>0.003</td>
</tr>
<tr>
<td>Peak cTnT, μg/L</td>
<td>3.03 (0.95–5.81)</td>
<td>4.36 (1.43–8.56)</td>
<td>0.008</td>
</tr>
<tr>
<td>Time to peak CK, h</td>
<td>7 (5–11)</td>
<td>8 (5–11)</td>
<td>0.991</td>
</tr>
<tr>
<td>Time to peak CK-MB, h</td>
<td>6 (5–9)</td>
<td>6 (5–9)</td>
<td>0.926</td>
</tr>
<tr>
<td>Time to peak cTnT, h</td>
<td>9 (6–13)</td>
<td>9 (6–12)</td>
<td>0.924</td>
</tr>
<tr>
<td>AUC_{48} CK</td>
<td>1134 (474–1886)</td>
<td>1571 (612–2597)</td>
<td>0.023</td>
</tr>
<tr>
<td>AUC_{48} CK-MB</td>
<td>117 (56–219)</td>
<td>171 (80–277)</td>
<td>0.006</td>
</tr>
<tr>
<td>AUC_{48} cTnT</td>
<td>2.92 (0.87–5.35)</td>
<td>3.31 (1.39–8.23)</td>
<td>0.032</td>
</tr>
<tr>
<td>AUC_{48} CK adjusted</td>
<td>1463 (600–2841)</td>
<td>2206 (1002–3781)</td>
<td>0.008</td>
</tr>
<tr>
<td>AUC_{48} CK-MB adjusted</td>
<td>172 (82–305)</td>
<td>296 (122–440)</td>
<td>0.001</td>
</tr>
<tr>
<td>AUC_{48} cTnT adjusted</td>
<td>4.00 (1.36–7.41)</td>
<td>6.22 (2.08–12.03)</td>
<td>0.004</td>
</tr>
</tbody>
</table>

Data are presented as median (IQR).
CK: creatine kinase, cTnT: cardiac troponin T, AUC: area under the curve.
Table 3 | Clinical outcome at 30 days in patients randomized to intracoronary or intravenous administration of abciximab

<table>
<thead>
<tr>
<th></th>
<th>Intracoronary (n=271)</th>
<th>Intravenous (n=263)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality</td>
<td>5 (1.8)</td>
<td>7 (2.7)</td>
<td>0.524</td>
</tr>
<tr>
<td>Cardiac mortality</td>
<td>4 (1.5)</td>
<td>6 (2.3)</td>
<td>0.492</td>
</tr>
<tr>
<td>TVR</td>
<td>9 (3.3)</td>
<td>10 (3.8)</td>
<td>0.764</td>
</tr>
<tr>
<td>Reinfarction</td>
<td>3 (1.1)</td>
<td>4 (1.5)</td>
<td>0.721</td>
</tr>
<tr>
<td>IST</td>
<td>1 (0.4)</td>
<td>3 (1.1)</td>
<td>0.366</td>
</tr>
<tr>
<td>MACEs</td>
<td>15 (5.5)</td>
<td>16 (6.1)</td>
<td>0.786</td>
</tr>
</tbody>
</table>

Data are presented as number (%).
TVR: target vessel revascularization, IST: in-stent thrombosis, MACEs: major adverse cardiac events.

Discussion

This study indicates that intracoronary administration of the GP IIb/IIIa inhibitor abciximab during primary PCI with thrombus aspiration compared with intravenous administration does not improve myocardial reperfusion as assessed by STR. However, intracoronary administration is related to improved myocardial reperfusion as assessed by MBG, as well as in the subset of patients with evaluable infarct size, to a 30% smaller enzymatic infarct size. The CICERO trial is the largest clinical trial to date to determine the effect of intracoronary versus intravenous administration of abciximab in STEMI patients undergoing primary PCI. Moreover, this is the first medium-scale trial performed in a contemporary cohort of STEMI patients who were treated with manual thrombus aspiration.

Abciximab acts as a potent inhibitor of platelet aggregation mainly by competitively binding to the GP IIb/IIIa receptor on the surface of activated human platelets. As a result of a higher affinity to this receptor, abciximab prevents binding of fibrinogen and von Willebrand factor to activated platelets, blocking the final common pathway for platelet aggregation. Experimental studies have suggested that abciximab has additional dose-dependent antiplatelet, antithrombotic, and antiinflammatory features. Abciximab not only prevents platelet aggregation in vitro but also promotes thrombus disaggregation. These findings suggest that a higher local concentration, achieved by intracoronary administration, results in improved outcome. Several small-scale studies have reported improved myocardial salvage, left ventricular functional recovery, and a smaller infarct size after intracoronary administration of abciximab. In a randomized trial in 154 patients by Thiele et al, STR as a continuous measure was higher in the intracoronary than in the intravenous group (77.8%
versus 70.0%). However, this positive study was powered to detect differences in infarct size and extent of microvascular obstruction by MRI. In the present study, which was powered to detect a clinically relevant improvement in STR, we could not confirm the positive findings as previously suggested. In contrast, we did observe a clinically relevant improvement in myocardial reperfusion as assessed by MBG and, in the subset of patients with evaluable enzymatic infarct size, a reduction in infarct size in patients randomized to intracoronary administration, which are consistent with the effects reported previously.25 Furthermore, the magnitude of the effect observed in this study was comparable.

Can the neutral findings on our primary end point be explained by differences between this and previous studies? In the positive study by Thiele et al,25 the patient population appeared to be at a higher clinical risk than in our study: patients presented with an ≈60-minute-longer ischemic time and a higher incidence of TIMI grade 0/1 flow, diabetes mellitus, and anterior infarction. In subgroup analysis, the benefit was observed in patients treated after 4 hours of symptom onset. Furthermore, high-dose clopidogrel preloading was performed in a small proportion of patients, and the use of thrombus aspiration was not reported. Our patient population resembled a recent neutral study with a similar baseline risk, including similar ischemic time, frequent use of clopidogrel preloading, and use of thrombus aspiration in 40%.26 Therefore, it is possible that the benefit of intracoronary administration on myocardial reperfusion was offset by a lower clinical risk and the routine use of thrombus aspiration in the present study.

The actual incidence of STR was higher than the estimated incidence used for sample size estimation. This estimation was based on data from the Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Myocardial Infarction (TAPAS) study performed in our center, which showed complete STR in 56.6% of patients randomized to thrombus aspiration.8 In a more recent trial, ADenosine Administration during and after Primary percutaneous coronary intervention in acute myocardial infarction Trial (ADAPT), however, the rate of complete STR was considerably higher (66.3%) and more similar to that in this study.17 It is therefore likely that the higher rate of STR is explained by differences in the rate of actual thrombus aspiration: TAPAS patients randomized to thrombus aspiration underwent thrombus aspiration in 84%, whereas 95% of patients in the ADAPT control group and 97% of CICERO patients underwent thrombus aspiration. Because the more recent STR data were not available during the design of CICERO, we could base our assumptions only on the TAPAS data. During the years after TAPAS, no significant changes took place that could explain the higher rates of STR.

We report an unexpected discrepancy between myocardial reperfusion as assessed by STR and by MBG; they are usually consistent in both positive and negative studies and in previous studies reporting on intracoronary abciximab.8,17,25 Several reasons may account for this discrepancy. One possible reason is that STR and MBG represent different
pathophysiological phenomena. MBG reflects mechanical patency of the microvasculature, whereas STR may reflect the functional status of the myocardial cells. Although both markers are widely accepted as surrogate end points of clinical outcome, restoration of myocardial reperfusion as defined by complete STR or MBG 2/3 is discordant in approximately one third of STEMI patients. Nevertheless, both markers are of independent prognostic value in predicting long-term mortality. Recently, however, the prognostic value of STR has been debated in patients treated with primary PCI. This discrepancy between both markers cannot be explained by the findings in this study and deserves further investigation. A second possible reason is that both markers are assessed at different time points after primary PCI: MBG directly after PCI and STR at 30 to 60 minutes after PCI. The beneficial effect of intracoronary administration on myocardial reperfusion may be present directly after PCI but not at 30 to 60 minutes after PCI. A discrepancy between myocardial reperfusion outcomes immediately after PCI and compared with later after PCI has been reported previously. A third possible reason is that intracoronary administration itself instead of abciximab improves myocardial reperfusion directly after PCI but negates it during the first hour after PCI. Although there was no control group with intracoronary injection of saline, it is not likely that intracoronary administration itself would also result in the relevant reduction in enzymatic infarct size that was also observed in this study.

In contrast to previous studies that have suggested reductions to >50% of the incidence of major adverse cardiac events at 30 days in patients randomized to intracoronary administration, we found no reduction or trend toward reduction. First of all, this study had insufficient power to detect differences in clinical events. Furthermore, this study was performed in patients receiving contemporary treatment, including prehospital administration of high-dose clopidogrel and thrombus aspiration. The absolute number of clinical events at 30 days was much lower in this trial than in these previous studies, making it even less likely to come to statistically significant improvements.

Although we observed conflicting results on myocardial reperfusion, the potential beneficial effects of intracoronary administration may become evident after 30 days. The reduction in enzymatic infarct size observed in a subset of patients may well translate into a better recovery of left ventricular function and improved clinical outcome at longer follow-up. Because this study was underpowered to detect possible differences in clinical events, larger randomized multicenter trials are needed to evaluate whether intracoronary administration during primary PCI improves clinical outcome. This is being investigated in an ongoing trial. In addition, local delivery of abciximab with a dedicated infusion catheter is currently being investigated in 2 trials that randomize STEMI patients to intracoronary bolus versus intravenous bolus (IC-ClearLy) and to intracoronary versus no bolus with or without thrombus aspiration in patients treated with bivalirudin (INFUSE AMI; http://www.ClinicalTrials.gov; unique identifier, NCT00976521).
Limitations
First, we performed an open-label study because blinding of the operator was not feasible. However, all end points were assessed in a blinded manner. Second, this study was powered on STR instead of a clinical end point. However, STR is strongly related to clinical outcomes and therefore is widely accepted as a surrogate marker. In addition, STR was measured in this study only as a categorization into 3 groups, thereby preventing direct comparison between this study and previous studies reporting on continuous STR. In general, categorization makes a measurement less sensitive to treatment differences. However, STR categorized into 3 groups is frequently used in medium-scale interventional trials to detect a clinically relevant improvement in STR. Third, we analyzed enzymatic infarct size in the subset of patients who were hospitalized in this center after PCI. However, the choice to stay in this center was based on geographical reasons and not biased by randomization. Fourth, all patients in this study received abciximab in a bolus-only strategy, which is not currently recommended. Bolus-only use is supported by studies showing that bolus-only use reduces bleeding complications and is not inferior to abciximab bolus with subsequent 12-hour infusion in stable and moderate- to high-risk patients with acute coronary syndromes. In this study, we did not compare the bolus-only strategy with the standard bolus with subsequent 12-hour infusion strategy. However, because infusion was not initiated in either randomization group, it has not influenced our comparison of intracoronary and intravenous administration. Finally, we did not investigate the effect of timing of intracoronary administration. Although previous studies have reported on intracoronary administration after wire passage but before restoration of epicardial flow, we chose to perform intracoronary administration after restoration of flow to have an optimal local concentration through the coronary artery both at the culprit site and in the distal microvasculature.

Conclusions
In STEMI patients undergoing primary PCI with thrombus aspiration, intracoronary administration of abciximab is not superior to intravenous administration in improving myocardial reperfusion assessed by STR as the primary end point. However, intracoronary administration is associated with improved myocardial reperfusion as assessed by MBG and, in the subset of patients with evaluable infarct size, a smaller enzymatic infarct size. Larger randomized multicenter trials are required to evaluate whether intracoronary administration reduces clinical adverse events.
Chapter 4

Acknowledgments
The authors thank the staff of the catheterization laboratory and coronary care unit and Wybe Nieuwland, MD, PhD, for their contributions in the acute care setting and Karim D.E. Mahmoud, BSc, and Margriet Couperus for their assistance in data collection.
References


PART II

Prognosis after acute myocardial infarction in routine clinical practice